前列腺组织雄激素：历史与当前临床相关性
Prostate tissue androgens: history and current clinical relevance.
作者信息
Marks Leonard S, Mostaghel Elahe A, Nelson Peter S
机构信息
Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA.
出版信息
Urology. 2008 Aug;72(2):247-54. doi: 10.1016/j.urology.2008.03.033. Epub 2008 May 27.
Abstract
Direct determination of androgen levels in prostate tissue provides a perspective on the organ that is not available via androgen serum levels. The principle prostatic androgens, primarily dihydrotestosterone (DHT) and secondarily testosterone, can be readily assayed in quick-frozen prostate biopsy cores or surgical specimens. Such assays have proved important in establishing (1) that DHT is a permissive factor in BPH pathogenesis, (2) a mechanism for the treatment of BPH, (3) an understanding of prostate cancer chemoprevention, (4) an explanation for the 'escape' of prostate cancer from castration therapy, (5) prostate safety of testosterone replacement therapy, and (6) insights into the cause of racial differences of prostate cancer. Future opportunities include clarification of new drug mechanisms for BPH and prostate cancer, as well as a better understanding of the pathogenesis of both, and as an aid in individual patient management. Determination of prostate tissue androgens may soon transition from research tool to clinical test.
摘要
直接测定前列腺组织中的雄激素水平，能提供一种通过雄激素血清水平无法获得的对该器官的观察视角。主要的前列腺雄激素，主要是二氢睾酮（DHT），其次是睾酮，可以在快速冷冻的前列腺活检组织芯或手术标本中轻松检测。这些检测已被证明在以下方面很重要：（1）确定DHT是良性前列腺增生（BPH）发病机制中的一个允许因子；（2）建立BPH的治疗机制；（3）理解前列腺癌化学预防；（4）解释前列腺癌对去势治疗的“逃逸”现象；（5）睾酮替代疗法的前列腺安全性；（6）深入了解前列腺癌种族差异的原因。未来的机会包括阐明治疗BPH和前列腺癌的新药机制，以及更好地理解两者的发病机制，并辅助个体患者管理。前列腺组织雄激素的测定可能很快会从研究工具转变为临床检测。
相似文献
1
Prostate tissue androgens: history and current clinical relevance.前列腺组织雄激素：历史与当前临床相关性
Urology. 2008 Aug;72(2):247-54. doi: 10.1016/j.urology.2008.03.033. Epub 2008 May 27.
2
Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.对来自良性前列腺增生和前列腺癌的原代细胞培养物进行MENT评估。
Int J Androl. 2009 Dec;32(6):607-15. doi: 10.1111/j.1365-2605.2008.00906.x. Epub 2008 Jul 9.
3
Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.前列腺内的睾酮和二氢睾酮。第一部分：良性前列腺增生和前列腺癌患者中的浓度和测定方法。
BJU Int. 2012 Jan;109(2):176-82. doi: 10.1111/j.1464-410X.2011.10651.x. Epub 2011 Oct 12.
4
Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.移行带中的睾酮和双氢睾酮水平与前列腺体积相关。
Prostate. 2017 Jul;77(10):1082-1092. doi: 10.1002/pros.23365. Epub 2017 Jun 8.
5
Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.非那雄胺对良性前列腺增生组织雄激素浓度的差异作用。
Clin Endocrinol (Oxf). 1997 Feb;46(2):137-44. doi: 10.1046/j.1365-2265.1997.950908.x.
6
Basis for hormonal management of advanced prostate cancer.晚期前列腺癌激素治疗的基础
Cancer. 1993 Feb 1;71(3 Suppl):1039-45. doi: 10.1002/1097-0142(19930201)71:3+<1039::aid-cncr2820711423>3.0.co;2-h.
7
Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.前列腺内的睾酮和二氢睾酮。第二部分：良性前列腺增生和前列腺癌患者雄激素激素治疗后的浓度。
BJU Int. 2012 Jan;109(2):183-8. doi: 10.1111/j.1464-410X.2011.10652.x. Epub 2011 Oct 12.
8
[Measurement of T and DHT contents in normal and diseased human prostate tissues].[正常及病变人类前列腺组织中睾酮和双氢睾酮含量的测定]
Zhonghua Wai Ke Za Zhi. 2000 Jul;38(7):545-7.
9
Conversion of 3H-testosterone to dihydrotestosterone in human hypertrophic prostatic tissue.人前列腺增生组织中3H-睾酮向二氢睾酮的转化
Nuklearmedizin. 1979;18(6):297-9.
10
Androgen of the human prostate.人类前列腺雄激素。
Endocr Res Commun. 1976;3(2):105-17. doi: 10.3109/07435807609052926.
引用本文的文献
1
Immune dysregulation in the prostates of C57BL/6 mice mirrors that seen in human benign prostatic hyperplasia.C57BL/6小鼠前列腺中的免疫失调反映了人类良性前列腺增生中的情况。
bioRxiv. 2025 Aug 15:2025.08.12.669857. doi: 10.1101/2025.08.12.669857.
2
Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.肿瘤内类固醇生成在去势抵抗性前列腺癌中的作用：治疗靶点。
Prostate Int. 2014 Sep;2(3):105-13. doi: 10.12954/PI.14063. Epub 2014 Aug 21.
3
RhoGDIα downregulates androgen receptor signaling in prostate cancer cells.RhoGDIα 下调前列腺癌细胞中的雄激素受体信号。
Prostate. 2013 Nov;73(15):1614-22. doi: 10.1002/pros.22615. Epub 2013 Aug 6.
4
A novel androgen signalling pathway uses dihydrotestosterone, but not testosterone, to activate the EGF receptor signalling cascade in prostate stromal cells.一种新的雄激素信号通路利用双氢睾酮而非睾酮来激活前列腺基质细胞中的表皮生长因子受体信号级联反应。
Br J Pharmacol. 2013 Oct;170(3):592-601. doi: 10.1111/bph.12307.
5
Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.前列腺癌易感性的种族差异：雄激素相关基因的遗传多态性。
Am J Cancer Res. 2013 Apr 3;3(2):127-51. Print 2013.
6
New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.采用 ASC-J9 通过靶向选择性前列腺细胞中的雄激素受体抑制去势抵抗性前列腺癌的新治疗方法。
Am J Pathol. 2013 Feb;182(2):460-73. doi: 10.1016/j.ajpath.2012.10.029. Epub 2012 Dec 4.
7
Current management of prostate cancer: dilemmas and trials.当前前列腺癌的治疗：困境与挑战。
Br J Radiol. 2012 Nov;85 Spec No 1(Spec Iss 1):S28-40. doi: 10.1259/bjr/13017671.
8
ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.ASC-J9 通过降解全长和剪接变异雄激素受体抑制去势抵抗性前列腺癌的生长。
Neoplasia. 2012 Jan;14(1):74-83. doi: 10.1593/neo.111436.
9
The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness.常见的性激素代谢途径基因中的遗传变异对甾体激素水平和前列腺癌侵袭性的影响。
Cancer Prev Res (Phila). 2011 Dec;4(12):2044-50. doi: 10.1158/1940-6207.CAPR-11-0283. Epub 2011 Sep 7.
10
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.穿心莲内酯作用于去势抵抗性前列腺癌中的雄激素受体通路。
Genes Cancer. 2011 Feb;2(2):151-9. doi: 10.1177/1947601911409744.
本文引用的文献
1
Tissue selectivity of the anabolic steroid, 19-nor-4-androstenediol-3beta,17beta-diol in male Sprague Dawley rats: selective stimulation of muscle mass and bone mineral density relative to prostate mass.合成代谢类固醇19-去甲-4-雄烯二醇-3β,17β-二醇在雄性斯普拉格-道利大鼠中的组织选择性：相对于前列腺质量，对肌肉质量和骨矿物质密度的选择性刺激。
Endocrinology. 2008 Apr;149(4):1987-93. doi: 10.1210/en.2007-0956. Epub 2007 Dec 20.
2
A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.一项使用睾酮凝胶和十一酸睾酮注射液进行的关于睾酮对性功能障碍及代谢综合征特征的剂量反应研究。
J Androl. 2008 Jan-Feb;29(1):102-5. doi: 10.2164/jandrol.107.002774. Epub 2007 Oct 3.
3
Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry.使用高效液相色谱/串联质谱法分析生物体液中作为肟衍生物的睾酮和双氢睾酮。
Rapid Commun Mass Spectrom. 2007;21(19):3200-6. doi: 10.1002/rcm.3205.
4
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.睾酮抑制后前列腺内雄激素及雄激素调节的基因表达持续存在：对去势抵抗性前列腺癌的治疗意义
Cancer Res. 2007 May 15;67(10):5033-41. doi: 10.1158/0008-5472.CAN-06-3332.
5
Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer.肾上腺雄激素的胞内代谢在雄激素依赖性前列腺癌中的重要性。
Prostate Cancer Prostatic Dis. 2007;10(3):301-6. doi: 10.1038/sj.pcan.4500956. Epub 2007 Mar 27.
6
Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.良性前列腺增生症和前列腺癌中主要雄激素的组织和血清水平。
Steroids. 2007 Apr;72(4):375-80. doi: 10.1016/j.steroids.2007.01.004. Epub 2007 Feb 13.
7
The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.度他雄胺对良性前列腺增生男性患者前列腺内二氢睾酮浓度的影响。
Prostate Cancer Prostatic Dis. 2007;10(2):149-54. doi: 10.1038/sj.pcan.4500931. Epub 2006 Dec 26.
8
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.睾酮替代疗法对迟发性性腺功能减退男性前列腺组织的影响：一项随机对照试验。
JAMA. 2006 Nov 15;296(19):2351-61. doi: 10.1001/jama.296.19.2351.
9
Prevention of benign prostatic hyperplasia disease.良性前列腺增生症的预防。
J Urol. 2006 Oct;176(4 Pt 1):1299-306. doi: 10.1016/j.juro.2006.06.022.
10
The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.双重5α-还原酶抑制剂度他雄胺对局限性前列腺癌的影响——前列腺癌根治术前4个月研究的结果
Prostate. 2006 Nov 1;66(15):1674-85. doi: 10.1002/pros.20499.
Zotero 插件